The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Ruben Mesa named executive director of the Mays Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Ruben Mesa was named executive director of the Mays Cancer Center. His appointment includes academic and research programming, as well as leading the cancer center’s patient care and clinical programs of the UT Health San Antonio MD Anderson affiliation.

Mesa’s appointment broadens the scope of responsibility in coordinating and integrating all aspects of cancer prevention, screening, care and survivorship with practice, education and research across UT Health San Antonio.

Mesa will also lead the integration and development of the inpatient cancer services for the new UT Health San Antonio Multispecialty and Research Hospital. This expanded appointment is part of the organization’s longer-term strategy for the Mays Cancer Center to earn comprehensive status from NCI.

Mays is an NCI-designated Cancer Center. Earning comprehensive status signifies that additional rigorous NCI standards are met.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account